it was developed by gilead sciences for use in the treatment of hiv infection and chronic hepatitis b and is applied in the form of tenofovir alafenamide fumarate taf closely related to the commonly used reverse transcriptase inhibitor tenofovir disoproxil fumarate tdf taf has greater antiviral activity and better distribution into lymphoid tissues than that agent vemlidy was approved by the u s food and drug administration fda in november 2016 gilead announced a phase iii clinical trial evaluating a single tablet regimen combining tenofovir alafenamide with cobicistat emtricitabine and elvitegravir and developed a coformulation of the drug with cobicistat emtricitabine and the protease inhibitor darunavir in a 48 week study comparing elvitegravir cobicistat emtricitabine tenofovir disoproxil trade name stribild to elvitegravir cobicistat emtricitabine tenofovir alafenamide trade name genvoya the results showed the newer drug to be noninferior to the established agent but at much lower dosages and with lower incidence of adverse side effects such as impaired kidney function the fda approved the taf based treatment regimen for treatment of hiv 1 in november 2015 genvoya is the first taf based regimen to receive approval